XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue
12 Months Ended
Dec. 31, 2022
Revenue.  
Revenue

Note 14.  Revenue

We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product:

Year Ended

December 31,

(In thousands)

2022

2021

2020

Revenue

Lymphedema products

$

212,266

$

202,913

$

187,130

Airway clearance products

34,519

5,144

Total

$

246,785

$

208,057

$

187,130

Percentage of total revenue

Lymphedema products

 

86%

 

98%

 

100%

Airway clearance products

14%

2%

N.M.

Total

 

100%

 

100%

 

100%

Our revenue by channel, inclusive of sales and rental revenue, for the years ended December 31, 2022, 2021 and 2020 are summarized in the following table:

Year Ended

December 31,

(In thousands)

2022

2021

2020

Private insurers and other payers

$

139,087

$

141,377

$

132,789

Veterans Administration

25,507

25,654

24,485

Medicare

47,672

35,882

29,856

Durable medical equipment distributors

34,519

5,144

Total

$

246,785

$

208,057

$

187,130

Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component.

The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable.

Rental revenue for the years ended December 31, 2022, 2021 and 2020, was primarily related to private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December 31, 2022, 2021 and 2020, was:

Year Ended December 31,

(In thousands)

2022

2021

2020

Sales-type lease revenue

$

35,440

$

30,143

$

25,633

Cost of sales-type lease revenue

 

11,190

 

9,622

 

9,011

Gross profit

$

24,250

$

20,521

$

16,622